ABPI Logo
  • Developing medicines
    • Responding to COVID-19
    • Clinical trials and research
    • Building a thriving environment for medicine discovery
    • UK-EU Future Relationship
    • Life Sciences Industrial Strategy
    • ABPI Medical Representatives Exam
  • Accessing medicines
    • How medicines are priced in the UK
    • Working with the NHS
    • Supply chain
    • Antimicrobial resistance (AMR)
    • Vaccines
    • What is the NICE Methods Review?
    • Rare diseases: Facing three challenges
  • Our ethics
    • ABPI Code of Practice
    • Disclosure UK
    • Appropriate prescribing
    • Patient & public involvement
  • Member representation
    • Events
    • Full membership
    • Working with our members​
    • ABPI Members List
    • Membership benefits
  • Who We Are
  • Media
  • Publications
  • Facts and Figures
  • Contact Us
MY ABPI LOGIN
 
  • The Association of the British Pharmaceutical Industry
  • Accessing medicines
  • Working with the NHS
  • A new ambition for cross-sector collaboration
  • Towards a new relationship

Towards a new relationship

Building collaboration between the NHS and the life sciences industry

• The NHS Confederation and The Association of the British Pharmaceutical Industry (ABPI) have agreed to develop a new ambition for cross-sector collaboration to help deliver the life sciences industrial strategy, the NHS Long Term Plan for England and corresponding strategic plans for health and care in other parts of the UK.

• The shared aim is to create a compact between the NHS and industry, which recognises their mutual dependence and seeks to stimulate collaboration, both in the development and testing of new products, and services and in the roll out of effective innovation in all its forms.

• There is a great deal that is underway at national and at local level which provides evidence that effective collaboration is possible and that it delivers results. Following the publication of the strategy, the UK government agreed two Life Sciences Sector Deals and the implementation of the Accelerated Access Collaborative. There has also been significant encouragement and support for Academic Health Science Networks (AHSNs) in England and corresponding collectives of industry, science, clinicians and academia in Scotland, Wales and Northern Ireland. Together these moves represent significant national leadership and focus which the NHS Confederation and The ABPI are keen to support and build on.

• At the same time, there is a shared acknowledgement that significant barriers to co-operation remain and that these need to be articulated and addressed. These include both ‘hard’ themes such as complexity, sustainability and scalability and so called ‘softer’ issues such as trust, ideology and culture.

• This discussion document builds on an initial roundtable which took place in London with leading figures from the NHS in England and industry, and begins to identify both the challenges and opportunities in transforming the relationship between the NHS and the life sciences industry. The aim now is to take that forward, stimulate discussion and start to develop a shared view of what needs to be done to overcome the obstacles that hamper progress, and build on current examples of successful partnership across the UK.

• This discussion document will be launched at Confed19, the NHS Confederation annual conference and exhibition, in Manchester in June 2019. It will initially be followed by engagement events in each of the seven health regions across England, which will consider how much progress has been made locally, and what needs to be done to stimulate more effective and faster innovation and partnership. Further events across the UK will also follow.

 

A new ambition for cross-sector collaboration

  • Towards a new relationship
  • Why this matters
  • What gets in the way?
  • What is possible? Rising to the challenge
  • Recommendations and call to action
  • Acknowledgements

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2021
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Disclosure UK
  • Frequently Asked Questions
  • Careers
  • Schools
  • Acronym buster

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.